<DOC>
	<DOCNO>NCT02632292</DOCNO>
	<brief_summary>Prospective , randomize , control , multicenter , open-label study compare everolimus-eluting bioresorbable vascular scaffold everolimus-eluting stent patient diabetes mellitus .</brief_summary>
	<brief_title>EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents Patients With Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Clinical inclusion criterion : Age ≥18 year DM type I II base definition American Diabetes Association Angiographically proven CAD Angina pectoris , equivalent symptom , and/or positive stress test , and/or instantaneous flow reserve ≤0.86 , and/or fractional flow reserve ≤0.80 Negative pregnancy test woman childbearing potential Angiographic inclusion criterion : Denovo lesion least one native coronary artery Luminal diameter reduction 5099 % assess visual estimation Target reference vessel diameter 2.5 4.0 mm Clinical exclusion criterion : Limited longterm prognosis lifeexpectancy &lt; 12 month Contraindications antiplatelet therapy Known allergy cobalt chrome , everolimus , polylactic acid Angiographic exclusion criterion : Target lesion locate leave main trunk Severe calcification target lesion determine angiography Instent restenosis Bifurcation lesion plan twostent strategy Chronic total occlusion Indication CABG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>